17q gain in neuroblastoma predicts adverse clinical outcome
Medical and Pediatric OncologyPublished 1 January 2001
Nick Bown, Maria astowska, Simon Cotterill, Seamus O’Neill, Caroline Ellershaw, Paul Roberts
Citations75
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
It is concluded that gain of chromosome segment 17q21-qter is of great biological and clinical importance in neuroblastoma, and that its detection at diagnosis should be a priority.
Abstract
We conclude that gain of chromosome segment 17q21-qter is of great biological and clinical importance in neuroblastoma, and that its detection at diagnosis should be a priority.
Keywords
MedicineBiochemistry, Genetics and Molecular Biology
Springer series in statisticsNonparametric Estimation from Incomplete Observations
45,533 Citations1992Edward L. Kaplan, Paul Meier
Journal of the American Statistical AssociationNonparametric Estimation from Incomplete Observations
39,052 Citations1958Edward L. Kaplan, Paul Meier
The American journal of pediatric hematology/oncologyBiology and Genetics of Human Neuroblastomas
236 Citations1997Garrett M. Brodeur, John M. Maris +3 more
It is proposed that neuroblastomas may be classified into three subsets with distinct biological features and clinical behavior, which allows more appropriate selection of therapeutic intensity to minimize side effects in those with a favorable outcome but optimize the chance of cure in those requiring aggressive treatment.
Journal of Clinical OncologyPrognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience--a pediatric oncology group study.
193 Citations1998Howard M. Katzenstein, Laura C. Bowman +12 more
It is confirmed that the survival of infants with stage D(S) NB is excellent, however, subsets of patients with poor prognosis can be identified by young age and unfavorable biologic factors.
PubMedGain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization.
185 Citations1997Dominique Plantaz, Gayatry Mohapatra +4 more
The high frequency of chromosome 17 gain and its association with bad prognostic factors suggest an important role for this chromosome in the development of neuroblastoma.
Medical and Pediatric OncologyAllelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma
174 Citations1995Huib N. Caron
LOH 1p was shown to be the most significant predictor of a poor outcome (P < 0.00001), independent of age and stage, and is also of prognostic value in those cases without N-myc amplification, indicating a stronger prognosticvalue for LOH 1 p.
Genes Chromosomes and CancerI;17 translocations and other chromosome 17 rearrangements in human primary neuroblastoma tumors and cell lines
149 Citations1994Nadine Van Roy, Geneviève Laureys +5 more
The data extend previous cytogenetic findings and suggest that, in addition to the known involvement of chromosome I, one or more genes on chromosome 17 also play a role in neuroblastoma development.
Genes Chromosomes and CancerGenetic heterogeneity of neuroblastoma studied by comparative genomic hybridization
139 Citations1998Jo Vandesompele, Nadine Van Roy +11 more
The presence of 3p, 11q or 14q deletions defines a genetic subset of neuroblastomas and contributes to the further genetic characterization of stage 3 and 4 tumors without MYCN amplification (MNA) and 1p deletion.
PubMedTranslocation involving 1p and 17q is a recurrent genetic alteration of human neuroblastoma cells.
109 Citations1994Larissa Savelyeva, Raffaella Corvi +1 more
It is reported that the deleted 1p material in cells of neuroblastoma lines is preferentially replaced by material from chromosome 17, resulting from an unbalanced 1;17 translocation.
European Journal of CancerGain of chromosome arm 17q predicts unfavourable outcome in neuroblastoma patients
109 Citations1997Maria Łastowska, Simon Cotterill +5 more
It is indicated that 17q changes have prognostic significance in neuroblastoma and should be a target for molecular cytogenetic detection at diagnosis.
The Journal of PathologyCOMPARATIVE GENOMIC HYBRIDIZATION (CGH) ANALYSIS OF NEUROBLASTOMAS—AN IMPORTANT METHODOLOGICAL APPROACH IN PAEDIATRIC TUMOUR PATHOLOGY
102 Citations1997C. Brinkschmidt, Holger Christiansen +5 more
Comparative genomic hybridization was applied to 35 neuroblastomas to obtain a global view of genetic imbalances and shows that CGH is a sensitive method for the detection of all prognostically relevant genetic alterations in neuroblastoma and considerably simplifies the Detection of these alterations.
Genes Chromosomes and CancerAdditional copies of a 25 Mb chromosomal region originating from 17q23.1-17qter are present in 90% of high-grade neuroblastomas
96 Citations1996Mounira Meddeb, Gisèle Danglot +9 more
The results indicate that chromosome 17 is rearranged very frequently in the form of unbalanced translocations with numerous chromosomal partners, all leading to the presence of supernumerary copies of a 25 Mb chromosomal region originating from 17q23.1‐qter.
PubMedComparative genomic hybridization study of primary neuroblastoma tumors. United Kingdom Children's Cancer Study Group.
92 Citations1997Maria Łastowska, E Nacheva +5 more
Genes Chromosomes and CancerPromiscuous translocations of chromosome arm 17q in human neuroblastomas
61 Citations1997Maria Łastowska, Paul Roberts +4 more
A remarkable promiscuity of translocation partners is indicated for neuroblastoma karyotypes involving 17q abnormalities, with more than 20 different chromosome regions involved in 17q translocations.
Genes Chromosomes and CancerMolecular cytogenetic delineation of 17q translocation breakpoints in neuroblastoma cell lines
38 Citations1998Maria fLastowska, Nadine Van Roy +6 more
The results suggest that the dosage of a gene, or genes, in 17q22–qter is responsible for the clinical effects of 17q gain, rather than the disruption of a specific gene.
Journal of Clinical OncologyStage 4S neuroblastoma: what makes it special?
36 Citations1998Katherine K. Matthay